MX2012011821A - Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas. - Google Patents

Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Info

Publication number
MX2012011821A
MX2012011821A MX2012011821A MX2012011821A MX2012011821A MX 2012011821 A MX2012011821 A MX 2012011821A MX 2012011821 A MX2012011821 A MX 2012011821A MX 2012011821 A MX2012011821 A MX 2012011821A MX 2012011821 A MX2012011821 A MX 2012011821A
Authority
MX
Mexico
Prior art keywords
viloxazine
base
solvent
reaction
compound
Prior art date
Application number
MX2012011821A
Other languages
English (en)
Spanish (es)
Inventor
Padmanabh P Bhatt
Likan Liang
David Dain
Jean-Philippe Taquet
Aleksadr Pechenov
Alexei Tchesnokov
Reynold Mariaux
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of MX2012011821A publication Critical patent/MX2012011821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2012011821A 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas. MX2012011821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32315110P 2010-04-12 2010-04-12
PCT/US2011/032013 WO2011130194A2 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Publications (1)

Publication Number Publication Date
MX2012011821A true MX2012011821A (es) 2012-11-30

Family

ID=44065289

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2012011821A MX2012011821A (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010358A MX357613B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010356A MX347218B (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010369A MX357614B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010368A MX355697B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2014010358A MX357613B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010356A MX347218B (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010369A MX357614B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010368A MX355697B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Country Status (8)

Country Link
US (7) US9403783B2 (cg-RX-API-DMAC7.html)
EP (1) EP2558437B1 (cg-RX-API-DMAC7.html)
JP (5) JP6196551B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011240773C1 (cg-RX-API-DMAC7.html)
CA (4) CA2795408C (cg-RX-API-DMAC7.html)
ES (1) ES2552166T3 (cg-RX-API-DMAC7.html)
MX (5) MX2012011821A (cg-RX-API-DMAC7.html)
WO (1) WO2011130194A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN108760719A (zh) * 2018-08-17 2018-11-06 北京理工大学 一种利用拉曼光谱分析cl-20的晶型纯度的方法
KR102927019B1 (ko) 2021-03-18 2026-02-13 슈퍼너스 파마슈티컬스, 인크. 치환된 몰폴린의 유도체 및 이의 용도
WO2023177845A1 (en) * 2022-03-18 2023-09-21 Supernus Pharmaceuticals, Inc. Process of making derivatives of substituted morpholines
WO2023248154A1 (en) * 2022-06-22 2023-12-28 Glenmark Life Sciences Limited Process for the preparation of viloxazine hydrochloride
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives
CN119707868A (zh) * 2023-09-27 2025-03-28 西安远大科创医药科技有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN119707851B (zh) * 2023-09-27 2026-08-11 远大医药(西安)有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN122422301A (zh) * 2023-12-18 2026-07-17 阿斯特罗森株式会社 (s)-维洛沙秦或其盐的改进制备方法
IT202400009022A1 (it) * 2024-04-19 2025-10-19 Cambrex Profarmaco Milano S R L Intermedi e processi per la preparazione di viloxazina

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
US3857839A (en) * 1969-06-20 1974-12-31 Ici Ltd For cyclising 1-aryloxy-3 beta-substituted ethylamino-2-propanols
ES411826A1 (es) * 1973-02-20 1976-01-01 Liade Sa Lab Procedimiento de obtencion de 1-ariloxi - 2 - propanolami- nas farmacologicamente activos.
JPS5188972A (en) 1975-01-29 1976-08-04 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho
JPS5283677A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Derivative of 2-(7-indenyloxymethyl)-4-substituted morpholine
US4711887A (en) 1982-04-23 1987-12-08 Imperial Chemical Industries Plc Hydrazinopyridazine compounds
JPH06306025A (ja) * 1992-11-30 1994-11-01 Sankyo Co Ltd ジアリールアルカン誘導体
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
AU4949996A (en) * 1995-03-10 1996-10-02 Nycomed Salutar, Inc. Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylmethyl-ethanol-amine sulphonate esters asintermediates
AUPO565997A0 (en) * 1997-03-17 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE19919153A1 (de) * 1999-04-27 2000-11-02 Consortium Elektrochem Ind Herstellung von acrylierten flüssigkristallinen Verbindungen
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20030040436A1 (en) * 2000-10-23 2003-02-27 Emerson Ralph W. Use of benzyl ester compositions for controlling non-arthropod pest populations
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
JP4210573B2 (ja) 2003-10-10 2009-01-21 花王株式会社 置換フェノキシプロパノールアミン類
JP4198183B2 (ja) * 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
US20060118002A1 (en) * 2004-12-03 2006-06-08 Sud-Chemie Inc. Organoclay composition containing quat mixtures
EP1924572B1 (en) * 2005-09-06 2009-12-30 SmithKline Beecham Corporation Regioselective process for preparing benzimidazole thiophenes
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN100415709C (zh) * 2006-05-15 2008-09-03 西北大学 β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途
WO2008047388A2 (en) * 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Improved process for the preparation of ranolazine
EP2285770B1 (en) * 2008-06-02 2015-05-20 Cipla Limited Process for the synthesis of arformoterol
US20100069390A1 (en) * 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US9296940B2 (en) * 2009-12-21 2016-03-29 Baker Hughes Incorporated Dithiazine derivatives
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
TWI596088B (zh) * 2011-01-25 2017-08-21 陶氏農業科學公司 4-胺基-6-(經取代的苯基)吡啶甲酸酯及6-胺基-2-(經取代的苯基)-4-嘧啶羧酸酯之芳烷酯以及其等作為除草劑之用途
TWI610929B (zh) * 2012-11-21 2018-01-11 拉夸里亞創藥股份有限公司 多形體形式

Also Published As

Publication number Publication date
JP2016006062A (ja) 2016-01-14
JP2018076325A (ja) 2018-05-17
US20190300492A1 (en) 2019-10-03
MX357613B (es) 2018-07-17
EP2558437A2 (en) 2013-02-20
WO2011130194A3 (en) 2012-01-05
US10005743B2 (en) 2018-06-26
ES2552166T3 (es) 2015-11-26
MX355697B (es) 2018-04-27
US20160304475A1 (en) 2016-10-20
MX347218B (es) 2017-04-20
CA2795408C (en) 2018-03-13
US9434703B2 (en) 2016-09-06
US20260008759A1 (en) 2026-01-08
MX357614B (es) 2018-07-17
US20220024885A1 (en) 2022-01-27
US9403783B2 (en) 2016-08-02
AU2011240773A1 (en) 2012-11-01
US10160733B2 (en) 2018-12-25
EP2558437B1 (en) 2015-08-05
JP2019194191A (ja) 2019-11-07
JP2017039754A (ja) 2017-02-23
US20110251198A1 (en) 2011-10-13
CA2992219A1 (en) 2011-10-20
AU2011240773B2 (en) 2015-04-02
US20150126735A1 (en) 2015-05-07
JP6663413B2 (ja) 2020-03-11
US20180265482A1 (en) 2018-09-20
WO2011130194A2 (en) 2011-10-20
CA3215310A1 (en) 2011-10-20
JP6196551B2 (ja) 2017-09-13
JP2013530129A (ja) 2013-07-25
AU2011240773C1 (en) 2015-08-27
CA2795408A1 (en) 2011-10-20
CA3126096A1 (en) 2011-10-20
CA3126096C (en) 2023-11-21

Similar Documents

Publication Publication Date Title
US20260008759A1 (en) Methods for producing viloxazine salts and novel polymorphs thereof
EP3645518B1 (en) Synthesis of omecamtiv mecarbil
EP2985277B1 (en) Method for preparing an atropisomer of a pyrrole derivative
AU2018244451A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
JP6523566B2 (ja) ジヒドロピリド環化合物の結晶形、製造方法および中間体
EP3386945A1 (en) Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
EP2462107A1 (en) Solid forms of an n-(phenylmethyl)propanamide derivative and processes of preparation
MXPA03003459A (es) Base venlafaxina cristalina y polimorfos novedosos de clorhidrato de venlafaxina, procesos para su preparacion.
WO2015188318A1 (en) Process for preparing quinazoline derivative
CN121194977A (zh) 用于制备芦可替尼及其新晶型的改良方法
EP4219443A1 (en) Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
CN115677680A (zh) 式i化合物的晶型及其制备和应用
WO2012085645A1 (en) Polymorphs of 3-chloro-4[(2r)-2
WO2007132990A1 (en) Process for the preparation of chiral glycidylphthalimide in highly optical purity
WO2018100565A1 (en) Process for the preparation of indoline compound

Legal Events

Date Code Title Description
FG Grant or registration